Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors

Jing Zhang, Qingyi Yang, Jan Antoinette C. Romero, Jason Cross, Bin Wang, Katherine M. Poutsiaka, Felix Epie, Douglas Bevan, Yuchuan Wu, Terence Moy, Anu Daniel, Brian Chamberlain, Nicole Carter, Joseph Shotwell, Anu Arya, Vipul Kumar, Jared Silverman, Kien Nguyen, Chester A. Metcalf, Dominic RyanBlaise Lippa, Roland E. Dolle

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Antibacterials with a novel mechanism of action offer a great opportunity to combat widespread antimicrobial resistance. Bacterial DNA Gyrase is a clinically validated target. Through physiochemical property optimization of a pyrazolopyridone hit, a novel class of GyrB inhibitors were discovered. Guided by structure-based drug design, indazole derivatives with excellent enzymatic and antibacterial activity as well as great animal efficacy were discovered.

Original languageEnglish
Pages (from-to)1080-1085
Number of pages6
JournalACS Medicinal Chemistry Letters
Issue number10
StatePublished - Oct 8 2015


  • Antibacterial
  • GyrB
  • MRSA
  • indazole
  • topoisomerase


Dive into the research topics of 'Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors'. Together they form a unique fingerprint.

Cite this